title: Case-control breast cancer study of MALDI-TOF proteomic mass spectrometry data on serum samples.
abstract: We introduce mass spectrometry proteomic research for diagnosis from a clinical perspective, with special reference to early-stage breast cancer detection. The nature of SELDI and MALDI mass spectrometric measurement is discussed. We explain how the mass spectral data arising from this technology may be viewed as a new data type. Some of the properties of the data are discussed and we show how such spectra may be interpreted. Sample preprocessing for mass spectrometry is introduced and a literature review of research in clinical proteomics is presented. Finally, we provide a detailed description of the study design on the breast cancer case-control study which is investigated in this special issue.
authors.affiliation: Leiden University Medical Center. m.p.j.van der werff@lumc.nl
authors.forename: Martijn P J
authors.initials: MP
authors.lastname: van der Werff
authors.forename: Bart
authors.initials: B
authors.lastname: Mertens
authors.forename: Mirre E
authors.initials: ME
authors.lastname: de Noo
authors.forename: Marco R
authors.initials: MR
authors.lastname: Bladergroen
authors.forename: Hans C
authors.initials: HC
authors.lastname: Dalebout
authors.forename: Rob A E M
authors.initials: RA
authors.lastname: Tollenaar
authors.forename: Andre M
authors.initials: AM
authors.lastname: Deelder
mesh_terms: D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D014408:Biomarkers, Tumor / Q000378:metabolism*; D001943:Breast Neoplasms / Q000175:diagnosis / Q000378:metabolism*; D016022:Case-Control Studies; D005260:Female; D006801:Humans; D008875:Middle Aged; D040901:Proteomics; D019032:Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization
chemical_list: D014408:Biomarkers, Tumor